Advertisement

Failure to Counsel Can Lead to Litigation

  • I. W. FongEmail author
Chapter
Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)

Abstract

Most senior physicians still in practice can recall their earlier experiences when patients were rarely informed about their disease, much less their medications. Most patients then (and still common in developing nations) were unaware of their diagnosis, names or types of medications and potential side effects. We have come a long way since then, but some patients still remain in the dark about their illnesses or medications. In the distant past, when physicians were held in high esteem and given unquestionable authority, treatment and investigations were ordered empirically without explanation or the patients’ input. Nowadays, the expectations are different and physicians are held accountable for making unilateral decisions. At present, in most developed countries, the approach to management of a patient’s condition is expected to be a joint venture between the physician and patient or family. This chapter will give case scenarios where the health care system (particularly physicians) have failed the patients by omission in providing adequate information and counselling.

Keywords

Pelvic Inflammatory Disease High Frequency Hearing Loss Gentamicin Level Vestibular Disturbance Medical Malpractice Litigation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Wilson WR, Thompson RL, Wilkowske CJ, Washington JA 2nd, Giuliani ER, Geraci, JE (1980). Short-term therapy for streptococcal infective endocarditis: combined intramuscular administration of penicillin and streptomycin. JAMA 245:360–363.CrossRefGoogle Scholar
  2. 2.
    Sexton DJ, Tenebaum MJ, Wilson WR, Steckelberg JM, Tice AL, Gilbert D, Dismukes W, Drew RH, Durack DT, and the Endocarditis Treatment Consortium Group (1998). Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Clin Infect Dis 27:1470–1474.PubMedCrossRefGoogle Scholar
  3. 3.
    Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr., Bolger AF, Levison ME, Ferrieri R, Gerber MA, Tanl LY, Gewitz, MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch J, Takahshi M, Tambert KA, (2005). Infective endocarditis: diagnosis, antimicrobial therapy and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Disease Society of America. Circulation III:e394–e432, DOI:10.1161/Circulation AHA 105.165564.CrossRefGoogle Scholar
  4. 4.
    Tunkel AR, Kaufman BA (2005). Cerebrospinal shunt infections. In: (eds.) Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases, 6th Edition. Elsevier/Churchill/Livingstone, Philadelphia, p. 1126–1132.Google Scholar
  5. 5.
    Morrisette I, Gourdeau M, Francoeur J (1993). CSF shunt infections: a fifteen-year experience with emphasis on management and outcome. Can. J Neurol Sci 20:118–122.Google Scholar
  6. 6.
    Fong IW, Tomkins KB (1985). Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 7:604–612.PubMedCrossRefGoogle Scholar
  7. 7.
    Fong IW (ed) (2009). Combination antimicrobial therapies. In: Emerging issues and controversies in infectious disease. Springer, New York, p. 337–377.Google Scholar
  8. 8.
    Pintado V, Cabellos C, Moreno S, Meseguer MA, Ayats J, Viladrich PF (2003). Enterococcal meningitis: a clinical study of 39 cases and review of the literature. Medicine; 82:346–364.PubMedCrossRefGoogle Scholar
  9. 9.
    Chapman PH, Borges LF (1985). Shunt infections: prevention and treatment. Clin Neurosurg 32:652–664.PubMedGoogle Scholar
  10. 10.
    Sweet RL, Gibbs RS (eds) (1985). Pelvic inflammatory disease. In: Infectious diseases of the female genital tract; Williams & Wilkins, p. 53–77.Google Scholar
  11. 11.
    Lipsky BA, Berendt AR, Deary HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C., Tan JS (2004). Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39:885–910.PubMedCrossRefGoogle Scholar
  12. 12.
    Fong IW (1996). Management of diabetic foot infection: a position paper. Can J Infect Dis 7:361–365.Google Scholar
  13. 13.
    Whelton A (1982). Renal tubular transport and intrarenal aminoglycoside distribution. In: (eds.) Whelan A, Neu HC. The aminoglycoside: microbial, classical use, and toxicology. Marcel Dekker, Inc., New York, p. 191–221.Google Scholar
  14. 14.
    Smith TR, Smith CR (1982). Risk factors for aminoglycoside nephrotoxicity. In: (eds.) Whelan A, Neu HC. The aminoglycoside: microbial, classical use, and toxicology. Marcel Dekker, Inc., New York, p. 401–415.Google Scholar
  15. 15.
    Brummett RE, Fox KE (1982). Studies of aminoglycoside ototoxicity in animal models. In: (eds.) Whelan A, Neu HC. The aminoglycoside: microbial, classical use, and toxicology. Marcel Dekker, Inc., New York, p. 453–486.Google Scholar
  16. 16.
    Blendush CL (1982). Ototoxicity: clinical considerations and comparative information. In: (eds.) Whelan A, Neu HC. The aminoglycoside: microbial, classical use, and toxicology. Marcel Dekker, Inc, New York, p. 453–486.Google Scholar
  17. 17.
    Guiliunas P, Dominguez-Moreno M, Lazarus JM, Lowrie EG, Gottlieb MN, Merrill JP (1978). Vestibular toxicity of gentamicin. Arch Intern Med 138:1621–1624.CrossRefGoogle Scholar
  18. 18.
    Chambers HF (2005). Aminoglycosides. In: (eds) Brunton LL, Lozo JS, Parker KL Goodman and Gilman: The pharmacological basis of therapeutics, 11th Edition, McGraw-Hill, New York, p. 1155–1171.Google Scholar
  19. 19.
    Bitner-Glindzicz M, Rachman S (2007). Ototoxicity caused by aminoglycosides is severe and permanent in genetically susceptible people. BMJ 335:784–785.PubMedCrossRefGoogle Scholar
  20. 20.
    Usami S, Abe S, Shinkawa H, Kimberling WJ (1998). Sensorineural hearing loss caused by mitochondrial DNA mutations: special reference to A1555G mutation. J Commun Disord 31:423–434.PubMedCrossRefGoogle Scholar
  21. 21.
    Estivill X, Goven N, Barcelo F, Badenas C, Romero ER, Moral L, Scozzri R, D’Urbano L, Zevianni M, Torroni A (1998). Familial progressive sensorineural deafness is mainly due to mt DNA A1555G mutation and is enhanced by treatment of aminoglycosides. Am J Hum Genet 62:27–33.PubMedCrossRefGoogle Scholar
  22. 22.
    Buchholtz K, Larsen CT, Hassager C, Bruun NE (2009). Severity of gentamicin’s nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin Infect Dis 48:65–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Cosgrove SE, Vigliani GA, Campion M, Fowler VG Jr, Abrutyn E, Corey R, Levine DP, Rupp M, Chambers HF. Karchmer AW, Boucher HW (2009). Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 48:713–721.PubMedCrossRefGoogle Scholar
  24. 24.
    Leibovici L, Vidal L, Paul M, (2009). Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 63:246–251.PubMedCrossRefGoogle Scholar
  25. 25.
    Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH, (1997). Once daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 39:677–686.PubMedCrossRefGoogle Scholar
  26. 26.
    Reeves DS, MacGowan AP, (1993). Once-daily aminoglycoside dosing. Lancet 341:895–896.PubMedGoogle Scholar
  27. 27.
    Berringer R, (2008). Aminoglycoside therapy balancing risk versus benefit. Risk identification for all physicians. Can Med Protect Assoc R10814E: www.cmpa-acpm.ca.edu.

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.St. Michael’s HospitalUniversity of TorontoTorontoCanada

Personalised recommendations